Using prescription-event monitoring to determine whether erythromycin estolate was a more frequent cause of jaundice than erythromycin stearate or tetracycline 12208 patients, for whom 5343 doctors had prescribed one of the three drugs, were identified by the Prescription Pricing Authority. Of the questionnaires sent to general practitioners about the possible occurrence of jaundice, 76% were returned. There were 16 reports of jaundice, of which four were attributable to gail stones, three to cancer, six to viral hepatitis, and only three were possibly related to an antibiotic. All three patients, in whom the antibiotic was a possible cause, had been treated with erythromycin stearate. No case was attributable to the estolate which had previously been suspected of being a more frequent cause of jaundice. Although the incidence is unknown, it is very unlikely to be more than one in 1000.
Introduction
In 1973 the Committee on Safety of Medicines reported that over an eight year period they had received a total of 48 reports of jaundice associated with erythromycin.' All but one of the patients had been treated with erythromycin estolate. Since this product accounted for less than half of the prescriptions issued by general practitioners, it seemed likely that the estolate -perhaps because it produces higher blood concentrations than other preparations-was appreciably more hepatotoxic. As far as is known, no deaths have ever been reported. Jaundice usually appears in 10 to 14 days, and sometimes more rapidly in patients who have previously been treated with erythromycin, and it clears rapidly after withdrawal of the antibiotic.
In 1980 the Drug Surveillance Research Unit was set up at the University of Southampton to develop improved methods for detecting and assessing drug risks and benefits. Its first major task has been to develop prescription-event monitoring.' Drug exposures in patients, identified from copies of prescriptions, are linked with adverse events subsequently recorded by their doctors on questionnaires (green forms) which are then sent to the unit. Recently we have used this technique to test the hypothesis that erythromycin estolate may be a more frequent cause of jaundice than another preparation of erythromycin.
Materials and methods
Prescriptions for erythromycin estolate (Ilosone, Dista), written in England between 1 January and 28 February 1982, were photocopied by the Prescription Pricing Authority and passed to the Drug Surveillance Research Unit. Prescriptions for the much more widely used erythromycin stearate (Erythrocin, Abbott) and tetracycline (Achromycin, Lederle) were also obtained from a random sample of 19 of the 90 family practitioner committee areas in England to provide a comparison. The Erythrocin sample was collected during the month of January and the Achromycin sample in February. When a doctor uses the approved name of a drug on his prescription, it is only possible to identify which formulation the patient received if the pharmacist has annotated the prescription with the name of the product that was dispensed. Our selection of cases was, therefore, restricted to patients whose treatment has been identified precisely by means of the brand name.
Questionnaires were prepared for up to six patients in any one doctor's practice. The patients were identified simply by a capital letter and the photocopies of the prescriptions, marked with the same capital letter, were pinned to the questionnaires. No copies were retained by the unit and the general practitioners were asked to retain the prescriptions for a few weeks as a means of identification in case further information should be needed. Practitioners were asked to note whether the prescriptions were the first to be issued during the present illness and whether or not the patients had developed jaundice.
Results
A when this antibiotic was used again in 1982. These three cases are not included in table II. In all these cases a letter was written to the general practitioner requesting further information. This was obtained in every case, and in none was the final diagnosis modified (table II) . There were five men and 12 women, whose ages ranged from 15 to 81 years. Tetracycline-In one of the two patients treated with tetracycline, jaundice was due to gall stone fragments in the common bile duct. In the second patient, who developed jaundice seven months after a course of treatment with tetracycline, no stones were found at operation and a liver biopsy showed changes of mild hepatitis. Neither case is attributable to the antibiotic.
Discussion
Warnings about the risk of jaundice have been included in the published reports about estolate for many years, whereas warnings have only recently appeared about the possibility that other preparations may also cause jaundice. It seems likely that this may have led to selective anecdotal reporting to national regulatory agencies.
The incidence of jaundice attributable to the estolate has been variously estimated as between 2% and 4%.3 The fact that none of more than 3000 patients treated with the estolate developed jaundice which was attributable to the drug suggests that its incidence is much lower. Our results suggest that it is very unlikely to be more than one per 1000 and probably a good deal lower. We hope that it may be possible to study a much larger series of patients at a future date, but in the meantime we see no reason for special concern about the safety of this antibiotic.
The most striking result from this investigation was the high level of cooperation by general practitioners. The green forms often included words of encouragement and support for the new method and many doctors also remarked about the extreme rarity, in their experience, of jaundice with any preparation of erythromycin. 
